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Abstract
Background Mucopolysaccharidosis I (MPS I) comprises a
spectrum of clinical manifestations and is divided into three
phenotypes reflecting clinical severity: Hurler, Hurler-
Scheie, and Scheie syndromes. There may be important
variations in clinical manifestations of this genetic disease
in patients residing in different regions of the world.
Methods Using data from the MPS I Registry (as of
September 2009), we evaluated patients from Latin America
(n=118) compared with patients from the rest of the world
[ROW (n=727)].
Results Phenotype distribution differed among patients in
Latin America compared to ROW (Hurler 31 vs. 62%, Hurler-
Scheie 36 vs. 21%, Scheie 10 vs. 11%, and unknown 22 vs.
6%). The frequency of certain symptoms, such as cardiac
valve abnormalities, sleep impairment, and joint contractures,
also differed between Latin America and ROW for some
phenotypes. Median age at MPS I diagnosis was earlier in the
ROW than Latin America for all phenotypes, and age at first
treatment for Hurler and Hurler-Scheie patients was also
earlier in the ROW. Hurler patients in Latin America showed a
gap of 3.1 years between median ages of diagnosis and first
treatment compared to only 0.5 years in the ROW. Treatment
allocation in Latin America compared to ROW was as
follows: enzyme replacement therapy (ERT) only, 80 vs.
45%; hematopoietic stem cell transplantation (HSCT) only,
0.9 vs. 27%; both ERT and HSCT, 0 vs. 16%; and neither
treatment, 19 vs. 13%.
Conclusion These data highlight important differences in
MPS I patients between Latin America and ROW in terms
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of phenotypic distribution, clinical manifestations, and
treatment practices.
Introduction
Mucopolysaccharidosis type I (MPS I; OMIM #252800) is
a rare condition, inherited in an autosomal recessive
manner. It is a lysosomal storage disorder caused by a
deficiency of alpha-L-iduronidase (IDUA) enzymatic activ-
ity, which in turn results in the accumulation of the
glycosaminoglycans (GAGs) heparan sulfate and dermatan
sulfate in organs and systems, ultimately leading to multi-
systemic cellular and organ dysfunction (Neufeld and
Muenzer 2001; Valstar et al. 2008). MPS I encompasses a
spectrum of clinical manifestations and is usually divided
into three phenotypes by clinical severity: Hurler, Hurler-
Scheie, and Scheie syndrome. Patients with Hurler syn-
drome develop symptoms in early childhood and have
marked cognitive delay (Neufeld and Muenzer 2001; Staba
et al. 2004; Wraith et al. 2005). Without treatment, life
expectancy is usually limited to the first decade (Neufeld
and Muenzer 2001; Pastores et al. 2007; Muenzer et al.
2009). At the other end of the spectrum, patients with
Scheie syndrome present with symptoms much later in
childhood and adolescence and show slower disease
progression. They have normal intelligence and survive
into adulthood, although they usually experience important
disease-related morbidity (Neufeld and Muenzer 2001;
Vijay and Wraith 2005; Thomas et al. 2006, 2010; Pastores
et al. 2007). Patients whose features are intermediate
between Hurler and Scheie syndromes are usually classified
as having Hurler-Scheie syndrome, which is generally
characterized by mild or no cognitive impairment (Neufeld
and Muenzer 2001; Pastores et al. 2007) and relatively
severe somatic symptoms limiting life expectancy to the
second or third decade in the absence of treatment (Pastores
et al. 2007; Muenzer et al. 2009). However, this traditional
subtype classification is not based on precisely defined
criteria and is not interpreted in a consistent fashion by all
practitioners (Pastores et al. 2007).
Currently two non-mutually exclusive therapeutic
options are available for MPS I: hematopoietic stem cell
transplantation (HSCT) and enzyme replacement therapy
(ERT) with laronidase (recombinant human α-L-
iduronidase; Aldurazyme©, Genzyme) (Cox-Brinkman et
al. 2006; Boelens et al. 2007; Pastores et al. 2007; Muenzer
et al. 2009). Cellular therapy through either derived bone
marrow or umbilical cord donor stem cells can induce a
remarkable change in the clinical course; reported trans-
plant outcomes include stabilization of neurocognitive
function if performed at a relatively early age—generally
before the age of 2 years—as well as prevention of fatal
cardiopulmonary complications and improvement in overall
survival (Cox-Brinkman et al. 2006; Boelens et al. 2007;
Aldenhoven et al. 2008). However, HSCT has little effect
on skeletal problems (Staba et al. 2004; Khanna et al. 2007;
Aldenhoven et al. 2008) and carries a significant procedural
risk (Cox-Brinkman et al. 2006; Aldenhoven et al. 2008).
The more recently developed ERT with laronidase (Wraith
et al. 2005; Wraith 2005) has been shown to improve
respiratory and cardiac symptoms and some skeletal and
joint manifestations, to reduce hepatosplenomegaly, and to
improve overall quality of life (Wraith et al. 2004; Wraith
2005; Sifuentes et al. 2007; Clarke et al. 2009). However,
ERT with laronidase at the labelled dose, 0.58 mg/kg, is not
expected to prevent cognitive decline as the blood-brain
barrier prevents the intravenously delivered enzyme from
reaching the central nervous system in significant amounts
(Kakkis et al. 2001; Wraith et al. 2005; Pastores et al.
2007). Early diagnosis and determination of phenotype are
therefore of major importance to determine the best
treatment option for each MPS I patient.
There are many variations in the clinical manifestations
of MPS I among individual patients, and there may also be
important differences in the clinical manifestations of
patients residing in different regions of the world. In the
present report, we undertook a study through the MPS I
Registry, the largest registry that tracks clinical data for
patients with MPS I, to characterize the phenotypes of
patients from the Latin America region and to compare
them with those of patients from the rest of the world
(ROW). The MPS I Registry (www.mpsiregistry.com) is an
international, observational, voluntary program initiated in
2003 to track treatment patterns and clinical status of
patients with MPS I over time in order to increase
understanding and awareness of this disease.
Methods
We characterized the phenotypes of patients enrolled in the
MPS I Registry from the Latin America region (all
countries from South America plus Mexico) and compared
them with those of patients in the Registry from the rest of
the world (ROW). All patients with MPS I are eligible to
participate in the MPS I Registry regardless of whether the
patient is receiving any treatment and independent of the
type of treatment the patient is receiving. There are no
exclusion criteria, all that is needed is a diagnosis
confirmation and a signed patient consent. While the focus
of the Registry is on prospective data capture, patients may
be enrolled posthumously in order to enhance the under-
standing of the natural history of MPS I.
Herein reported analyses were conducted using data
available as of September 2009. The data analyzed were the
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number of patients enrolled in each region, phenotype
distribution, the most frequent symptoms, age at onset of
symptoms, age at diagnosis, age at initiation of treatment,
and type of treatment. Numerical comparisons were made,
but formal statistical evaluations were not performed and no
P-values were generated for these comparisons.
The MPS I Registry Program has the approval of ethics
committees. A specific ethics approval for this paper was
not required; supporting documents are available upon
request.
Results
As of September 2009, 845 patients were enrolled in the
MPS I Registry worldwide. A total of 118 patients were
enrolled from five countries in Latin America (60% Brazil,
14% Argentina, 17% Mexico, 3% Chile, and 5% Colombia)
as shown in Fig. 1. The ROW patient group totaled 727
patients from 27 countries: 56% from Europe, 41% from
North America, and 3% from Asia Pacific. Patients from
Brazil made up the majority of Latin American patients.
The phenotype distribution for Latin American patients and
patients from the ROW is presented in Fig. 2a. The
distribution of phenotypes for Registry patients in these
two regions appeared to be different, with 31% of Latin
American patients reported to have Hurler syndrome, while
in ROW patients Hurler was the most common phenotype
accounting for 62% of patients. Overall there was a higher
proportion of patients in Latin America for whom the
phenotype was undetermined or unreported (22 versus 6%
in the ROW). Figure 2b displays the phenotype distribution
of patients enrolled in Latin America stratified by country.
Hurler was the most common phenotype reported in
patients in Argentina, Colombia, and Mexico, while
Hurler-Scheie syndrome accounted for the majority of
patients with MPS I disease in Brazil and Chile. However,
it should be kept in mind that there is a fairly large
percentage of patients with missing or undetermined
phenotype, and the sample sizes for some countries such
as Chile and Colombia are quite small.
Phenotype classification is expected to be related to the
age at onset of MPS I symptoms, although there are many
other contributing factors. The median ages at onset of
MPS I–related symptoms are summarized in Fig. 3. This
figure shows similar ages at symptom onset for the Hurler
patients, Scheie patients, and patients with an undetermined
or missing phenotype in Latin America compared to ROW.
However, the Hurler-Scheie patients in Latin America
seemed to have a younger age at symptom onset than the
Hurler-Scheie patients in the ROW (1 year versus 2.2 years).
The median ages at MPS I diagnosis and first treatment
(ERT or HSCT) by phenotype are also presented in Fig. 3.
Hurler patients in Latin America showed a delay of
3.1 years between the median age of diagnosis and the
median age of first treatment, while Hurler patients in the
ROW were generally treated earlier, with a corresponding
delay of only 0.5 years. Conversely, Scheie patients in Latin
America showed a delay of 8.5 years from diagnosis to first
treatment, while in the ROW the delay was 5.7 years.
Registry data regarding laronidase treatment regimens were
also analyzed. No major differences in dose, dose frequen-
cy, or infusion time between Latin American and ROW
patients were apparent. Most patients in both regions were
reported to receive laronidase at the dose recommended on
the drug label (0.58 mg/kg intravenously once a week).
The symptom profile in MPS I is expected to differ
across phenotypes, but not necessarily by region. Figure 4
displays the frequencies of key MPS I signs and symptoms
reported in patients at the time of enrollment in the
Registry, according to phenotype and region. Only those
signs reported in at least 40% of Latin American patients,
by phenotype, are presented. Several apparent regional
differences in symptom frequency were seen. In Hurler
patients, joint contractures were reported in 97% of Latin
America patients but in only 52% of patients in the ROW.
Other clinical findings reported more frequently in Latin
American Hurler patients compared to ROW included
cognitive impairment (89 versus 62%), sleep disturbance
(89 versus 64%), enlarged tongue (89 versus 49%),
dysostosis multiplex (81 versus 60%), and enlarged tonsils
(68 versus 39%). Conversely, cardiac valve abnormalities
were reported in 73% of ROW Hurler patients but in only
35% of Latin American Hurler patients. In Hurler-Scheie
patients, differences in symptom frequency were slightly
less apparent. Joint contracture was reported in 90% of
Latin American patients but in only 78% of patients in the
ROW, and pneumonia was reported in 48% of Latin
American patients compared to only 21% of ROW patients.
Conversely, cardiac valve abnormalities were reported in
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87% of ROW but in only 54% of Latin American Hurler-
Scheie patients. A similar frequency of cognitive impair-
ment was reported in 33% of Latin American and 35% of
ROW Hurler-Scheie patients. In Scheie patients, the
symptoms with the largest regional difference in frequency
were sleep disturbance (75% Latin America, 42% ROW),
cardiac valve abnormalities (67% Latin America, 95%
ROW), and hepatomegaly (83% Latin America, 55%
ROW). Among patients with an undetermined or missing
phenotype, differences in frequency by region of 15% or
more were noted for most symptoms with the exception of
enlarged tongue, corneal clouding, sleep disturbances/
snoring, scoliosis, and kyphosis/gibbus, each of which
occurred in a similar percentage of patients in Latin
America and the ROW. Such variation is likely due to a
wide array of phenotypes in this group. Of note, the
frequency of cognitive impairment was lower in Latin
American compared to ROW patients with an undeter-
mined or missing phenotype (31 versus 53%).
Of the 118 enrolled patients in Latin America, 80% were
reported to have received ERT only, 0.9% to have received
HSCT only, 0% both ERT and HSCT, and 19% were
reported to have received neither HSCT nor ERT. Of 727
Registry patients in the ROW, 45% received ERT only, 27%
received HSCT only, 16% received both ERT and HSCT,
and 13% received neither treatment. Treatment status by
phenotype is presented in Fig. 5. This analysis revealed that
63% of Hurler patients in the ROW received HSCT with or
without ERT, while in Latin America the primary treatment
for Hurler patients was ERT alone (83% of Latin American
Hurler patients).
Discussion
The MPS I Registry has emerged as the largest database for
monitoring the clinical progression of MPS I disease
worldwide. The design and methodology of the program
have enabled the acquisition of a population sample that is
diverse in its composition and representative of the
heterogeneous nature of MPS I (Pastores et al. 2007;
Thomas et al. 2010). The data presented here give the Latin
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American population numbers for several parameters
regarding disease onset, symptomatology, and treatment
decision options.
The enrollment data suggest a different MPS I phenotype
distribution in Latin America compared to ROW, with Latin
America reporting a smaller proportion of Hurler patients
(31 versus 62%) and a higher proportion of Hurler-Scheie
patients (37 versus 21%) and patients with an unknown or
undetermined diagnosis (22 versus 6%). There also
appeared to be phenotype distribution differences among
the individual Latin American countries. However, the
sample size in Latin America was relatively small (n=118),
and therefore caution should be used when interpreting
these data. In addition, 60% of patients enrolled from Latin
America were from Brazil, and the majority of observed
trends are likely to be driven by this subgroup. The
remaining 40% of patients were widely distributed among
the other Latin American countries, making it impossible to
assess more definitive differences among patients from the
different countries.
Some of the differences observed between Latin Amer-
ica and the ROW with respect to phenotype may be due to
pediatricians from Latin America who are not familiar with
MPS I and lack ready access to diagnostic methods, and
therefore misclassify some patients with severe disease
(Hurler) as having moderate (Hurler-Scheie) disease. In this
regard, Latin America also had a higher proportion of
patients with an undetermined phenotype than in the ROW
(22 versus 6%). The age of diagnosis and of symptom onset
was very young for a high proportion of Latin American
patients with an unknown or undetermined phenotype,
suggesting that many or most are actually Hurler patients.
Thus, the discrepancy in phenotype distribution may not be
as marked as it appears. Cognitive impairment is one of the
main features that differentiate Hurler patients from Hurler-
Scheie and Scheie. Had some Latin American Hurler
patients been misdiagnosed as Hurler-Scheie, one might
have expected to see a higher proportion of Latin American
Hurler-Scheie patients with cognitive impairment. Howev-
er, the frequency of cognitive impairment in Hurler-Scheie
patients was similar between Latin America and ROW (33
versus 35%). In addition, the group of patients with an
unknown or undetermined diagnosis in Latin America
actually had a lower frequency of cognitive impairment
than in the ROW (31 versus 53%). These findings are
consistent with there being a true phenotypic difference in
MPS I patients from Latin America.
It is also important to bear in mind that the population of
Latin America includes ancestors of European immigrants
as well as an indigenous population, which could result in a
different mix of genotypes and associated phenotypes as
compared to the ROW. Although in some cases genotyping
may be helpful in identifying patients with Hurler syn-
drome (Terlato and Cox 2003), genotyping is not routinely
done in Latin America, and therefore the genotype data
currently available in the MPS I Registry are too sparse to
draw any conclusions. In the future, genotyping of Latin
American patients may be helpful in further elucidating the
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phenotype distribution as certain genotype-phenotype cor-
relations may allow the prediction of a patient’s clinical
phenotype from the genotype. As genotyping becomes
more common in the future, this topic will be an interesting
avenue to pursue.
The different age at symptom onset for Hurler-Scheie
patients may indicate regional variations in conventions
for assigning phenotype to MPS I. Apparent differences
in the prevalence of certain symptoms may indicate
regional phenotype differences but may also be closely
related to regional practices in evaluating, diagnosing,
and following MPS I patients. For instance, the higher
observed rate of cognitive impairment in Latin American
Hurler patients may correspond to the fact that HSCT is
not performed in Hurler patients in Latin America but is
a relatively common treatment option in many other
countries globally. Following the same rationale, the
differences reported in valvular compromise may reflect
less clinical monitoring and follow-up in Latin America
than in the ROW, where there are more facilities to
provide more regular evaluations with echocardiograms.
In addition, in some countries in Central and South
America, pediatricians receive less clinical training in the
diagnosis of inborn errors of metabolism, and there are a
limited number of specialized centers for the diagnosis,
assessment, and treatment of these diseases.
Treatment information available from the MPS I Regis-
try shows that while the majority of Hurler patients
worldwide receive HSCT, this treatment is not routinely
performed in most regions in Latin America. Only one
Latin American patient (phenotype unknown) in the
Registry has received HSCT. The later age at diagnosis of
Hurler patients in Latin America than in the ROW may be
one reason why HSCT is uncommon in countries where it
is available. By the time many Hurler patients are
diagnosed, they are beyond the age of 2 years, and thus
have missed the optimum window of time for a successful
transplant. In these cases ERT is likely administered to
provide somatic benefits and to manage the other non-CNS-
related complications of the disease.
Fig. 4 Prevalence of MPS
I–related symptoms by region
and phenotype
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Overall, 19% of Latin American patients and 13% of the
ROW patients received no disease-specific treatment. Some
of these patients may have been diagnosed before laroni-
dase became commercially available, and some patients
may live in regions with limited access to treatment.
Furthermore, patients with delayed diagnosis and severe
neurological involvement may elect to receive palliative
care instead of some of the specific treatments. Further
analyses of treatment choice and time to treatment using
data from the MPS I Registry should account for the time
83
91
83
58
23
87 87
44
4
40
6 1 7
23
2
1617
9
17
39
14
5 11
33
0%
20%
40%
60%
80%
100%
Hurler Hurler-Scheie Scheie Undetermined
/ Missing
Hurler Hurler-Scheie Scheie Undetermined
/ Missing
Phenotype
Pa
tie
nt
s 
re
po
rti
ng
tr
ea
tm
en
t 
ERT HSCT ERT + HSCT Neither
Latin America Rest of World
Fig. 5 Treatment status by MPS
I phenotype and region
Scheie
0 10 20 30 40 50 60 70 80 90 100
Enlarged tongue
Splenomegaly
Toe-walking
Dysostosis multiplex
Cardiac valve abnormalities
Coarse facial features
Sleep disturbances/snoring
Hernia
Hepatomegaly
Corneal clouding
Joint contractures
% of Patients
Rest of World (N=79) Latin America (N=12)
0 10 20 30 40 50 60 70 80 90 100
Scoliosis
Hip dysplasia
Genu valgum
Cardiac valve abnormalities
Chronic otitis media
Dysostosis multiplex
Kyphosis/Gibbus
Enlarged tongue
Enlarged tonsils
Sleep disturbances/snoring
Hernia
Corneal clouding
Splenomegaly
Joint contractures
Hepatomegaly
Coarse facial features
% of Patients
Rest of World (N=43) Latin America (N=26)
Undetermined/Missing
Fig. 4 (continued)
J Inherit Metab Dis (2011) 34:1029–1037 1035
period in which patients are diagnosed and the availability
of ERT and HSCT as treatment options. Further information
is required to better establish optimum treatment manage-
ment for MPS I patients irrespective of locality but taking
into account real local treatment options. In this sense,
management guidelines developed in Latin American
countries (Martins et al. 2009) are of major importance,
and such guidelines should be reconsidered periodically to
reflect local conditions.
The fact that MPS I is a progressive disease with
variable rates of irreversible features, disease awareness, or
lack thereof has important implications for the effectiveness
of treatment. As mentioned above, the best outcomes for
HSCT occur in patients under age 2 with normal develop-
mental quotients at the time of transplant. Findings from a
recent study inMPS I dogs treated from birth with intravenous
ERT demonstrated that very early treatment could prevent the
development of certain disease-related complications, e.g.,
skeletal and valve dysplasia, that are otherwise refractory to
treatment once established (Dierenfeld et al. 2010). Gabrielli
et al. reported the case of a boy with attenuated MPS I who
started ERT with laronidase at 5 months of age and
compared his clinical course to that of his older sibling,
who did not began treatment until 5 years of age. After
5 years of treatment, the younger sibling had not developed
any clinical manifestations of MPS I except for mild corneal
clouding. In contrast, although many of the older sibling’s
clinical features had improved, some, although stabilized,
had persisted (Gabrielli et al. 2010).
These findings underscore the importance of heightened
disease awareness as a key component to proactive
diagnosis and early treatment. Physicians must be educated
on which early clinical symptoms to look for in order to be
able to identify and diagnose MPS I patients in a proactive
manner. Some early disease manifestations, e.g., otitis
media and hernia, are very common in MPS I patients but
also relatively common in the general population and would
not necessarily raise clinical suspicion of MPS I. Unusual
clinical signs and symptoms of MPS I that are more
specific and commonly present by age 2 include coarse
facial features, corneal clouding, enlarged tongue and
tonsils, sleep disturbance, hepatosplenomegaly, cardiac
valve abnormalities, joint contractures, dysostosis multi-
plex, kyphosis/gibbus, and cognitive impairment (Pastores
et al. 2007). As disease awareness increases, it will be
interesting to see if the observed differences in phenotype
persist.
An important consideration in interpreting the data
presented in this study is the voluntary and observational
nature of the MPS I Registry. As with all observational
studies, there exists the potential for ascertainment and
reporting biases. Nonetheless, the differences in phenotype
distribution, prevalence of clinical manifestations, and
management practices observed between the Latin Amer-
ican region and the ROW raise intriguing questions that
should be investigated in greater depth. The findings in this
study, together with further data accumulated through the
MPS I Registry on an ongoing basis, provide support
towards the development of a better understanding of
disease progression and management in Latin America.
Conclusion
The results of this study suggest a different phenotype
distribution of MPS I patients from Latin America than in
the ROW. Apparent differences in the age of symptom
onset and prevalence of certain symptoms may indicate
regional phenotype differences but may also be related to
regional practices in evaluating, diagnosing, and following
MPS I patients. These data should be confirmed with larger
patient numbers, which will provide additional information
to support a better understanding of MPS I disease
progression and management in Latin America versus the
ROW.
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